Probiotic Reduces Infant Respiratory Infections by Thirty Percent

October 1, 2010

A probiotic called Bifidobacterium animalis subsp. lactis BB-12 (BB-12) reduced the rate of respiratory infections in newborn babies by 30%, according to research published in the British Journal of Nutrition last week.

A probiotic called Bifidobacterium animalis subsp. lactis BB-12 (BB-12) reduced the rate of respiratory infections in newborn babies by 30%, according to research published in the British Journal of Nutrition last week.

In the double-blind, placebo-controlled study, researchers in Finland and Denmark tested the effects of two daily doses of the probiotic (as a tablet) versus a control tablet in 109 healthy one-month old babies up until eight months of age. Breast-feeding durations and symptoms of respiratory infections were recorded.

At eight months, 95% of the control group experienced respiratory infections compared to 65% of the BB-12 group. No differences in breast-feeding duration were recorded across the two groups.

BB-12 is supplied by Chr. Hansen (Hørsholm, Denmark). For more information on the probiotic, visit Chr. Hansen here.